Verici Dx plc (LON:VRCI – Get Free Report) hit a new 52-week low during mid-day trading on Thursday . The company traded as low as GBX 2.50 ($0.03) and last traded at GBX 2.69 ($0.03), with a volume of 145282 shares changing hands. The stock had previously closed at GBX 2.63 ($0.03).
Verici Dx Stock Performance
The company’s fifty day simple moving average is GBX 4 and its two-hundred day simple moving average is GBX 5.96. The company has a market capitalization of £6.37 million, a price-to-earnings ratio of -131.25 and a beta of 1.59. The company has a quick ratio of 8.49, a current ratio of 4.54 and a debt-to-equity ratio of 4.65.
Verici Dx Company Profile
Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.
Featured Articles
- Five stocks we like better than Verici Dx
- Using the MarketBeat Dividend Tax Calculator
- Fast-Growing Companies That Are Still Undervalued
- Manufacturing Stocks Investing
- Top Cybersecurity Stock Picks for 2025
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Archer or Joby: Which Aviation Company Might Rise Fastest?
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
